Overview of Биосон

Property	Description
Active ingredient	Doxylamine succinate, Passiflora incarnata extract
Form	Tablet (Oral dosage form)
Pharmacological class	Sedative and Hypnotic agent
General purpose	Management of transient insomnia and nervous tension
Origin	Combined (Synthetic and Phyto-component)

1. Defining Биосон: Type, Class, and Identity

Биосон is defined as a combination drug preparation, fundamentally classified as a sedative and hypnotic agent, primarily designed to address non-organic sleep disorders. Its synthetic component, Doxylamine, is categorized as a first-generation histamine H₁-receptor antagonist. This classification relates to its ability to reduce alertness and promote drowsiness. Биосон is supplied exclusively as an oral dosage form, specifically a tablet, which establishes the necessary route of administration for the systemic delivery of its active components.

2. Doxylamine and Passiflora: Composition and Origin

The unique nature of Биосон stems from its dual composition, integrating both a synthetic chemical substance and a plant-derived component. The synthetic ingredient is Doxylamine (typically Doxylamine succinate), which is primarily responsible for the hypnotic action. The formulation is complemented by Passiflora incarnata extract (Passionflower), which is prepared as a homeopathic attenuation (3 CH) and functions as a phyto-drug with traditional calming properties. The use of Passiflora preparations for generalized anxiety and restlessness is established in the context of its traditional properties. This blend signifies a product of mixed origin, utilizing the established chemical properties of an H₁-antagonist alongside a natural component traditionally used for nervous support.

3. General Purpose and Action Principle

The general therapeutic purpose of Биосон is the effective management of transient situational insomnia and the alleviation of general nervous tension contributing to sleep onset difficulty. The medication achieves this through a synergistic action that involves two distinct physiological actions: central nervous system quieting, provided by the synthetic component, and supplementary nervous tension relief, supported by the natural extract. This combined principle is intended to facilitate the physical and mental relaxation required to fall asleep, supporting a return to regular sleep patterns.

What side effects are possible with Биосон?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the potential side effects of this medicine primarily based on the actions of the Doxylamine component, a first-generation antihistamine.

Frequency and System-Organ Classes

The most common adverse reactions are those related to the central nervous system (CNS) and anticholinergic activity. These include drowsiness (somnolence), dizziness, dry mouth, and constipation. Other common effects include headache and general fatigue.

These reactions are grouped into official system-organ classes, such as Nervous System Disorders (drowsiness, dizziness) and Gastrointestinal Disorders (dry mouth, constipation). Less frequently, the regulatory profile notes effects such as blurred vision (Eye Disorders) and urinary retention (Renal and Urinary Disorders).

Time-Related Patterns and Serious Safety Considerations

Drowsiness and other CNS effects are documented as being more prominent at the start of treatment. Furthermore, official regulatory documents note the risk of tolerance development and potential dependence when sedative-hypnotic agents are used for prolonged periods.

Serious potential reactions explicitly documented in safety labeling include severe sedation leading to impaired psychomotor performance, which restricts activities like driving. The anticholinergic properties present a serious safety concern for individuals with pre-existing conditions such as narrow-angle glaucoma or prostatic hypertrophy, which are listed as key restrictions. Rare, but possible, severe hypersensitivity reactions are also included in the overall safety documentation.

Population-Specific Safety Notes

The official safety profile specifies that older adults may have an increased sensitivity to the anticholinergic effects, potentially leading to confusion or an increased risk of falls. The safety profile also indicates that effects like sedation may be more pronounced in individuals with hepatic or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of the primary active component is officially characterized by anticholinergic toxicity. Documented manifestations include signs such as mydriasis (dilated pupils), tachycardia (rapid heart rate), hyperthermia, flushing, and urinary retention. Central Nervous System (CNS) effects are also listed in regulatory documents, encompassing delirium, hallucinations, psychosis, and various states of impaired consciousness.

The regulatory profile strictly defines the severe, life-threatening outcomes that require immediate attention. These documented complications include the progression to grand mal seizures, respiratory failure, severe cardiac arrhythmias, and ultimately coma or cardiorespiratory arrest. Regulatory documents also note the risk of rhabdomyolysis, which can lead to acute renal failure.

Official guidance mandates seeking immediate emergency medical attention for any suspected overdose. Emergency services must be contacted immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management is defined as symptomatic and supportive care, requiring procedures such as continuous cardiac monitoring and the use of activated charcoal administration under professional supervision. Regulatory information also specifies that children appear to be at a high risk for cardiorespiratory arrest in the context of Doxylamine overdosage.

Therapeutic Uses of Биосон

What Биосон Treats: Main Uses and Benefits

The synthetic component of the medication is intended for the management of short-term insomnia.

The medication is relevant in contexts marked by increased discomfort or tension and is used for managing transient, occasional insomnia and symptoms of stress-related nervous restlessness. It is applied across situations involving difficulty falling asleep, mental agitation, and emotional irritability that interfere with the mind’s ability to quiet down before bed.

The primary focus of this supportive therapy is the management of symptoms that interfere with sleep onset. The therapeutic context notes: “It contributes to easing the overall symptom load by supporting the patient during difficult episodes of mental agitation.” This product is applied in clinical settings that involve acute or unstable symptom patterns, such as sleeplessness linked to temporary life events like overwork or mild jet lag. It helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Nervous Restlessness The formulation provides the key therapeutic benefit of inducing a state of drowsiness and relaxation, and it contributes to improving comfort during periods of heightened symptoms.

Regulatory References

NIH MedlinePlus overview of Doxylamine

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory guidelines define specific populations for whom the medicine is approved, restricted, or strictly prohibited. Use is established for adults and adolescents 12 years of age and older for the temporary relief of insomnia.

Absolute Contraindications

The medicine is contraindicated and must not be used by two primary groups:

Patients with known hypersensitivity to doxylamine or any related antihistamines.
Patients who are concurrently taking Monoamine Oxidase Inhibitors (MAOIs).

Age-Related Restrictions

Age Group	Regulatory Status
Children (< 12 years)	Not recommended; safety and efficacy not established.
Older Adults (Geriatric)	Avoid use; due to increased risk of anticholinergic effects and confusion.

Conditional Restrictions (Use with Caution)

Conditional use is required for individuals with certain pre-existing conditions sensitive to the drug’s properties. Caution is recommended for patients with narrow-angle glaucoma, conditions causing urinary retention (such as prostatic enlargement), severe cardiovascular disorders, and certain breathing problems (e.g., chronic bronchitis).

Caution is also necessary for those with hepatic (liver) or renal (kidney) impairment.

Pregnancy and Lactation

Use of the medicine as a sleep aid is officially avoided or not recommended during both pregnancy and lactation.

What should I know about interactions with other medicines?

Interaction Scope and Restrictions

The official regulatory documentation for the active component, Doxylamine succinate, defines several specific interaction categories. Medicinal product categories with documented interactions include Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) depressants (such as sedatives, hypnotics, and opioid analgesics), and other anticholinergic agents.

Official Interaction Classifications

The most stringent classification is the contraindication of co-administration with MAOIs and other ethanolamine derivative antihistamines. MAOIs are prohibited because they are documented to intensify and prolong adverse CNS effects due to inhibited clearance.

Pharmacodynamic and Substance Restrictions

The primary mechanistic basis for other restrictions is pharmacodynamic reinforcement, which results in additive CNS depression or enhanced anticholinergic toxicity. Consequently, co-administration with Alcohol (Ethanol) is formally not recommended due to the risk of severe drowsiness and falls.

Official labels also note that taking the tablet with food may delay the onset of action and reduce the overall absorption of the medicine. Furthermore, patients with hepatic or renal impairment may be at a greater risk of enhanced interaction severity, as the drug's clearance is dependent on these functions.

Connection to the Overall Interaction Profile

The regulatory interaction profile requires avoiding additive CNS effects and mitigating anticholinergic toxicity. This defines combinations with MAOIs as contraindicated and strongly restricts use with alcohol and other sedating agents, while advising caution regarding administration timing and in specific patient populations.

Mechanism of Action

The active component of Биосон functions as an inverse agonist at specific sites on the mathrmGABAmathrmA receptor complex. This molecular interaction primarily focuses on receptors containing alpha 1 subunits, which are concentrated in regions of the brain associated with somnolence regulation. Upon binding, the compound allosterically modifies the receptor's conformation, resulting in the facilitation of mathrmCl^- ion flux across the neuronal membrane. This increased ion flow intensifies the hyperpolarization of the postsynaptic neuron. The resulting enhancement of mathrmGABAergic inhibitory neurotransmission subsequently increases the overall inhibitory tone within the central nervous system (mathrmCNS). This cascade of events leads to the modulation of electrophysiological activity, specifically promoting brain wave patterns characteristic of non-rapid eye movement (mathrmNREM) sleep stages. Following absorption and distribution to target tissues, the compound undergoes rapid hepatic metabolism.

Dosage and Administration Information

How to Use Биосон: Official Administration Guidelines

Биосон is an oral formulation that is formulated for administration in accordance with the established parameters for its primary synthetic component, Doxylamine succinate. The administration route for this product is oral (by mouth) as a tablet.

Dosing and Schedule

For adults and adolescents 12 years of age and older, the standard dose is 25 mg of Doxylamine succinate (or its equivalent in the combination product). This represents the maximum amount to be taken in any 24-hour period.

The frequency of use is limited to once daily (qHS). The tablet should be taken approximately 30 minutes before bedtime to align with the desired onset of its action, and generally consumed with a glass of water.

Duration and Use Constraints

This medication is designed for short-term use only, addressing transient or occasional sleeplessness. Continuous use should not exceed a duration of two consecutive weeks. If sleeplessness continues beyond this period, professional medical input is required.

A critical administration constraint is that the dose must only be taken when the user can commit to a full, uninterrupted period of sleep, typically defined as seven to eight hours. The product is not recommended for children under 12 years of age for the insomnia indication.

Summary of Administration

Feature	Official Labeled Instruction
Route of Administration	Oral (by mouth)
Standard Single Dose	25 mg Doxylamine equivalent
Timing	30 minutes before retiring
Maximum Duration	No longer than two consecutive weeks

Recent Clinical Evidence

Research Evidence / Overview of Studies for Биосон

This summary outlines the types of research and the study patterns reported for the active components of Биосон, focusing on evidence described in regulatory and peer-reviewed scientific literature. It does not offer clinical recommendations or personal health advice.

Evidence for Use in Transient Situational Insomnia and Sleep Onset Difficulty

Research exploring how the synthetic component, Doxylamine, is studied for sleep difficulties has primarily involved Randomized Controlled Trials (RCTs). These short-term studies, often lasting only one to two weeks, were applied in research contexts involving episodic or acute sleep patterns in non-pregnant adults. The studies measured outcomes such as the time subjects reported it took to fall asleep (sleep latency), as well as the total duration of sleep they reported. Systematic reviews describe patterns observed in the studies where the synthetic ingredient was associated with increased reports of drowsiness when taken at night. The evidence base for the sedative properties of this component has been examined in short-term use scenarios. However, research is still lacking on the specific role or contribution of the herbal component (Passiflora) to the primary outcome of reducing sleep latency in this particular combination.

Evidence for Addressing Nervous Tension and Restlessness

Evidence exploring nervous tension has been primarily developed from studies and traditional use documentation related to the herbal component, Passiflora incarnata extract. Research has explored this component in smaller clinical trials and observational settings. The studies collected patient-reported outcomes describing perceived discomfort and tension. Findings describe patterns observed in these studies where the use of Passiflora was associated with subjective reports of calmness and changes in agitation over defined time intervals. The available evidence is often based on traditional use documentation and smaller-scale studies, rather than large-scale, definitive RCTs.

Long-Term Studies and Duration of Follow-Up

The available research exploring this medicine focuses on evidence relevant to trials assessing short-term or episodic symptom patterns. The primary efficacy studies on the synthetic component have limited follow-up durations, typically measuring outcomes only over a few days up to two weeks. Long-term outcomes, such as the duration of sustained effect or patterns related to long-term use, are not fully established.

What is Still Uncertain About Биосон's Research Base

A limitation noted in the research is the availability of high-quality comparative trials that specifically investigate the combined effect of the two active ingredients versus each component alone. Research has explored each ingredient, but the combined action principle is not fully characterized by extensive, dedicated combination product trials. Furthermore, the evidence quality varies across studies, particularly for the herbal component, which relies heavily on smaller-scale trials.

Key Studies & References

Doxylamine - StatPearls - NCBI Bookshelf (Review on indications, action, and contraindications for doxylamine)

Frequently Asked Questions (FAQ)

Common questions about Биосон (FAQ)

Q: What is the general duration of effect for a typical dose of Биосон?

A: The duration of the active component's presence in the body is characterized by its elimination half-life. Official information states that this half-life for doxylamine generally ranges from 7 to 15 hours.

This measure describes the time it takes for half of the substance to be eliminated, indicating that effects may persist for many hours after the dose is taken.

Q: Is it normal to feel a little groggy the morning after taking Биосон?

A: Regulatory information notes that the active component, doxylamine, is associated with residual next-day effects. These can include feelings of drowsiness, grogginess, or tiredness.

To minimize the risk of these residual morning effects, the prescribing information references the need for a full 7 to 8 hours of uninterrupted sleep.

Q: Why is Биосон sometimes prescribed for conditions other than sleep issues?

A: The synthetic component of the medicine, Doxylamine, is officially approved for uses that extend beyond sleep difficulties. In some jurisdictions, the component is indicated for the relief of general allergy symptoms.

Furthermore, in certain specific combination formulations (usually with pyridoxine), Doxylamine is approved for managing nausea and vomiting during pregnancy (NVP).

Q: Is it possible for Биосон to interact with vitamins or herbal supplements?

A: Official guidance references the importance of consultation with a healthcare provider or pharmacist regarding the use of vitamins and herbal supplements before starting this medicine.

This caution is necessary due to the possibility that some supplements could interfere with the actions of the active component or increase the risk of certain side effects.

Q: What kinds of symptoms might indicate an allergic reaction to Биосон?

A: Regulatory documents state that rare but possible severe hypersensitivity reactions are a safety concern. These reactions may be indicated by symptoms such as a skin rash, itching, hives, or swelling.

More seriously, swelling of the face or throat, chest tightness, or trouble breathing are listed as potential signs of a severe allergic event.

Q: Does Биосон cause weight gain, according to research?

A: Postmarketing reports associated with the active component, doxylamine, have included mentions of changes in appetite. Specifically, increased appetite and weight gain have been reported in some contexts.

This information is gathered from ongoing safety surveillance rather than from initial efficacy trials.

Q: What happens if I forget to take a dose of Биосон?

A: Official guidance references a procedure where the dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory text references skipping the missed dose and continuing the regular schedule.

Official regulatory guidance includes a specific warning against taking extra medicine to compensate for a forgotten dose.

Q: Do studies suggest that Биосон affects dream patterns?

A: While the overall effect on general dream patterns is not comprehensively detailed in the core documentation, regulatory postmarketing reports have included mentions of specific side effects on sleep perception.

These effects associated with the active component have included reports of nightmares.

Q: What should a person do if they experience unusual side effects from Биосон?

A: Official guidance states that any severe or unusual effects should be reported to a healthcare provider or pharmacist immediately.

Timely reporting of adverse events helps maintain comprehensive safety monitoring for the medicine.

Q: Is it described anywhere that Биосон can be taken with pain relievers?

A: Official interaction profiles specifically warn against using this medicine concurrently with Central Nervous System (CNS) depressants, which includes opioid pain relievers.

This warning exists because the combination poses a risk of dangerously additive sedation. Official information indicates that consultation is necessary when combining any medicines.

Q: What is the standard regulatory status of Биосон in different countries?

A: The regulatory classification of the active components varies depending on the country and the formulation. The single component Doxylamine is often available in pharmacies as an over-the-counter (OTC) sleep aid.

However, certain combination products containing Doxylamine may be classified as prescription-only in some jurisdictions.

Q: Do existing studies address whether Биосон affects mood?

A: Official safety reports list potential effects on mental state and perception, which are covered under psychiatric side effects. These reports have included symptoms such as anxiety, confusion, disorientation, irritability, and nervousness.

These are recognized potential effects that are monitored in the medicine’s safety profile.

Q: Is it true that Биосон is a non-benzodiazepine drug?

A: The active component, Doxylamine succinate, is pharmacologically classified as a first-generation antihistamine (H₁-receptor antagonist).

This classification places it in a chemical class that is distinct and separate from benzodiazepine medications.

Q: Is there any information about Биосон affecting blood pressure?

A: Official warnings note that caution is required in patients who have pre-existing severe cardiovascular disorders. The drug is not used to treat blood pressure, but it can have an impact.

Some reports, particularly related to discontinuation, have mentioned the potential for effects such as orthostatic hypotension (a drop in blood pressure when changing posture).

Q: Are there any documented cases of overdose with Биосон?

A: Regulatory documentation includes a list of symptoms associated with overdose of the active component. These symptoms are documented for monitoring and clinical reference.

Signs of overdose can include dizziness, mental confusion, enlarged pupils, a fast heartbeat, and the potential for hallucinations.

Q: How long after stopping Биосон do its effects typically clear the body?

A: The body’s process for eliminating the active component, doxylamine, is characterized by its elimination half-life, which generally ranges from 7 to 15 hours.

This pharmacokinetic information indicates the speed at which the drug is processed, with complete clearance typically achieved after a period of several half-lives.

Q: Is it necessary to have a medical examination before starting Биосон?

A: Official guidance references the importance of consultation with a healthcare provider before starting this medicine. This is a crucial step even if the product is available without a prescription.

Consultation helps determine the medicine's appropriateness for the individual based on their specific health conditions and other medicines being taken.

Q: Is a withdrawal effect possible when stopping Биосон?

A: Official guidance on stopping sedating antihistamines notes the potential for withdrawal symptoms. This is distinct from dependence but is a recognized effect.

These effects are generally described as mild and may include symptoms such as dizziness, nausea, headache, or anxiety.

Q: Does the package insert for Биосон mention any risk of hallucinations?

A: Official side effect reports associated with the active component do list the risk of mental and mood changes. These effects are particularly noted in cases of overdose.

These reported changes include the potential for hallucinations.

Q: Is Биосон widely available in pharmacies, or is it highly restricted?

A: The synthetic component, Doxylamine succinate, is commonly available over-the-counter (OTC) as a single ingredient sleep aid in various countries. This indicates wide access in pharmacies.

However, the overall availability of the specific Биосон combination product depends on local regulatory classification.

How should Биосон be stored and disposed of?

How to Store and Dispose of Биосон

Official regulatory guidelines dictate precise conditions for storing and disposing of this medicine to maintain its potency and integrity.

Storage Requirements

Item	Labeled Regulatory Statement
Temperature	Store at a controlled room temperature, typically below 25 C or 30 C.
Protection	Keep the medicine in its original container and outer carton to protect it from light and moisture.
Handling	Do not freeze the tablets. Refrigeration is generally prohibited unless explicitly directed by the label.
Safety	The product must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Биосон must be disposed of according to local regulations for pharmaceutical waste. The official instruction prohibits discarding the medicine in household trash or flushing it down wastewater systems, ensuring environmentally responsible handling of the product.

Биосон